Moderna Inc. ($MRNA) Stock Forecast: Down 6.6% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company known for its innovative mRNA-based vaccines and therapies. The company has been at the forefront of the fight against infectious diseases and cancer.

Why is Moderna Inc. going down?

MRNA stock is down 6.6% on Apr 24, 2026 16:42

• Moderna (MRNA) recently saw a decrease in its stock price, potentially related to the upcoming financial report projecting an expected decrease in EPS and revenue, as well as ongoing financial difficulties and insider selling.
• This downward trend could be influenced by negative profit margins, projected annual losses, and challenges resulting from reductions in U.S. government funding for its bird-flu initiative.
• While the recent approval of mCOMBRIAX in the EU and ongoing Phase 3 trial for a bird-flu vaccine may have provided some positive momentum, concerns about the company's financial performance appear to have overshadowed these advancements in its product pipeline.
• Investors may be exercising caution due to conflicting signals regarding Moderna's financial prospects and the competitive environment within the biotechnology sector, illustrated by expansions in the CMV infection and iPSC-derived NK cells portfolios.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna (MRNA) Expected to Announce Earnings on Friday

Moderna (MRNA) is slated to release its Q1 2026 earnings before market open on Friday, May 1st, with analysts forecasting a loss of ($2.03) EPS and $251.0 million in revenue. The company faces ongoing financial challenges, including negative margins and projected yearly losses, despite potential boosts from EU approval of mCOMBRIAX and a Phase 3 bird-flu vaccine trial. Recent insider selling and past U.S. funding cuts for its bird-flu program are noted headwinds.

https://www.marketbeat.com/instant-alerts/moderna-mrna-expected-to-announce-earnings-on-friday-2026-04-24/

Cytomegalovirus (CMV) Infection Pipeline Set for Strategic Expansion Through 2026 with 20+ Therapies and Robust Innovation from ModernaTX, Helocyte, VBI Vaccines, and GSK | DelveInsight

The Cytomegalovirus (CMV) infection pipeline is poised for significant expansion through 2026, with over 20 therapeutic candidates from companies like ModernaTX, Helocyte, VBI Vaccines, and GSK driving innovation. The focus is shifting towards next-generation vaccines, antiviral innovations, and immune-targeted strategies to address this persistent viral threat, especially for immunocompromised individuals and congenital CMV. Key developments include mRNA-based platforms, viral vector technologies, and T-cell-based therapies, indicating a move towards more effective and preventive solutions.

https://www.barchart.com/story/news/1490725/cytomegalovirus-cmv-infection-pipeline-set-for-strategic-expansion-through-2026-with-20-therapies-and-robust-innovation-from-modernatx-helocyte-vbi-vaccines-and-gsk-delveinsight

iPSC-Derived NK Cells Pipeline Set to Transform Cancer Immunotherapy Landscape with 15+ Emerging Therapies and Strong Innovation Momentum from Century Therapeutics, Fate Therapeutics | DelveInsight

The iPSC-derived NK cell therapeutic landscape is undergoing a significant transformation with over 15 emerging therapies in development by companies like Century Therapeutics and Fate Therapeutics. These advancements in cellular engineering and immuno-oncology aim to revolutionize cancer treatment through scalable, off-the-shelf therapies for various hematological malignancies and solid tumors. DelveInsight's report highlights the pipeline's rapid innovation, strategic collaborations, and the integration of advanced technologies like CAR-NK engineering and gene editing to enhance therapeutic efficacy and address existing challenges in cancer treatment.

https://www.barchart.com/story/news/1490267/ipsc-derived-nk-cells-pipeline-set-to-transform-cancer-immunotherapy-landscape-with-15-emerging-therapies-and-strong-innovation-momentum-from-century-therapeutics-fate-therapeutics-delveinsight

Moderna, Inc. (MRNA) Presents at ESCMID Global 2026 - Slideshow (NASDAQ:MRNA) 2026-04-23

Moderna, Inc. (MRNA) delivered a presentation at the ESCMID Global 2026 event. The company published a slide deck in conjunction with this presentation. The article notes that Seeking Alpha's transcripts team covers thousands of quarterly earnings calls and is expanding its coverage.

https://seekingalpha.com/article/4893728-moderna-inc-mrna-presents-at-escmid-global-2026-slideshow?source=feed_all_articles

Thermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company

Thermo Fisher Scientific CEO Marc Casper stated that the Waltham-based company is already benefiting from domestic manufacturing efforts, anticipating further growth in the coming years. This "tailwind" is expected to be buoyed by onshoring initiatives, with former President Donald Trump having recently toured a Thermo Fisher facility to highlight his administration's focus on lowering drug prices and boosting domestic production.

https://www.bizjournals.com/boston/news/2026/04/23/thermo-fisher-us-manufacturing.html

Trending Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Up 11.3% Today

Deere & Company ($DE) Stock Forecast: Down 5.1% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Up 6.7% Today

Intel Corporation ($INTC) Stock Forecast: Up 22.7% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 14.1% Today

Boston Scientific Corporation ($BSX) Stock Forecast: Down 5.3% Today

NVIDIA Corporation ($NVDA) Stock Forecast: Up 5.0% Today

Cadence Design Systems Inc. ($CDNS) Stock Forecast: Up 5.7% Today

ServiceNow Inc. ($NOW) Stock Forecast: Up 5.1% Today

The Trade Desk Inc ($TTD) Stock Forecast: Up 5.9% Today

Moderna Inc. Price History

02.03.2026 - MRNA Stock was down 5.2%

• Moderna's decline in stock value could be linked to concerns regarding slow enrollment in COVID-19 vaccine trials, mirroring issues observed with Pfizer and BioNTech. This trend suggests potential difficulties in gathering post-marketing data and a waning interest in COVID-19 vaccines.
• The temporary pause in vaccine trial enrollment may have instilled uncertainty among investors concerning the vaccine development timeline and regulatory clearance, resulting in a negative impact on Moderna's stock performance.
• Investor attention appears to be shifting towards other biotech entities such as Allogene Therapeutics, benefiting from positive sector trends and experiencing a rise in stock prices. This redirection of focus and investment away from Moderna potentially contributed to its recent decline.

02.03.2026 - MRNA Stock was down 5.7%

• Moderna's stock experienced a bearish movement today, possibly influenced by:
• Pfizer and BioNTech halting enrollment in a large U.S. COVID-19 vaccine trial due to slow recruitment, reflecting potential challenges and decreased interest in vaccine trials.
• Market sentiment shifting towards Allogene Therapeutics, which is gaining momentum in the biotechnology sector with positive clinical pipeline developments, diverting attention from Moderna.
• Mixed trade ideas and technical analyses on Moderna's stock from traders, indicating uncertainty and varied perspectives on its future movements.
• The bearish trend in Moderna's stock today could be a result of concerns regarding vaccine trial enrollment, competition in the biotech sector, and divergent market analyses, leading to a decline in investor confidence in the short term.

24.03.2026 - MRNA Stock was down 6.6%

• Moderna (MRNA) recently saw a decrease in its stock price, potentially related to the upcoming financial report projecting an expected decrease in EPS and revenue, as well as ongoing financial difficulties and insider selling.
• This downward trend could be influenced by negative profit margins, projected annual losses, and challenges resulting from reductions in U.S. government funding for its bird-flu initiative.
• While the recent approval of mCOMBRIAX in the EU and ongoing Phase 3 trial for a bird-flu vaccine may have provided some positive momentum, concerns about the company's financial performance appear to have overshadowed these advancements in its product pipeline.
• Investors may be exercising caution due to conflicting signals regarding Moderna's financial prospects and the competitive environment within the biotechnology sector, illustrated by expansions in the CMV infection and iPSC-derived NK cells portfolios.

01.03.2026 - MRNA Stock was up 5.3%

• The recent upward trend in Moderna's stock price can be linked to its strategic shift towards oncology research and the development of next-gen respiratory solutions, underscoring a focus on sustained growth opportunities extending beyond the realm of pandemic-related vaccines.
• Investor enthusiasm is likely fueled by Moderna's dedicated efforts in oncology, particularly the promising outcomes in personalized neoantigen therapy for melanoma, signaling positive market responses to the company's diversification.
• Moderna's target of achieving profitability by 2028, backed by a substantial cash reserve and a recent legal settlement, instills further confidence among investors regarding the company's trajectory.
• Noteworthy progress in resolving the ongoing patent dispute with Arbutus Biopharma Corp (ABUS) may have also contributed to the positive momentum of Moderna's stock, as a favorable resolution in legal matters could help alleviate uncertainties for stakeholders.

21.03.2026 - MRNA Stock was up 1.7%

• Moderna's upward market trajectory can be linked to a sequence of favorable occurrences and disclosures:
• Approval of a dual flu and COVID-19 vaccine targeted at older adults in the EU, demonstrating the company's ongoing success in broadening its product offerings.
• Disclosure of encouraging data during the AACR 2026 annual meeting, particularly regarding the impressive response rates seen with mRNA-4359 in melanoma patients, underscoring the potential of Moderna's treatment methodologies.
• Participation in forthcoming investor conferences, underscoring Moderna's proactive approach to engaging with shareholders and showcasing advancements in mRNA technology.
• The downturn observed in Boston Scientific's stock might have indirectly influenced Moderna's upward trend, as investors potentially redirected their attention to firms within the healthcare sector with more promising growth opportunities.

23.03.2026 - MRNA Stock was down 5.2%

• The decline in Moderna's stock value could be linked to a notable loss in U.S. government funding for its mRNA research. However, the company showed recovery as it began a Phase 3 trial for an mRNA bird flu vaccine.
• Despite the European Commission approving Moderna's COVID-19-influenza combination vaccine, it was not sufficient to counterbalance the impact of the funding loss from the U.S., prompting concerns among investors regarding the company's financial well-being.
• Investor focus on Regeneron Pharmaceuticals, reinforced by Cantor Fitzgerald's "Overweight" rating and strong quarterly EPS results, potentially diverted attention from Moderna, contributing to the downward trend in its stock performance.
• Additionally, the optimistic prospects for Thermo Fisher Scientific, driven by onshoring initiatives, may have attracted investor interest away from Moderna's ongoing challenges, further influencing its stock price.

27.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock experienced a significant drop today, possibly influenced by the broader market sentiment affected by the U.S.-Iran conflict and policy deadlines.
• The internal realignment by Vanguard, resulting in 0 reported shares, might have also contributed to the downward pressure on Moderna's stock.
• Despite ongoing growth potential from strategic partnerships and promising pipelines, the stock faced short-term selling pressure, reflecting investor concerns.
• The market's negative reaction to the overall uncertainty and rising oil prices could have led to the decline in Moderna's stock, creating potential buying opportunities for investors eyeing high-quality stocks.

08.03.2026 - MRNA Stock was up 5.5%

• Moderna's surge in the market may be linked to optimistic views on its international COVID-19 vaccine markets, emphasized by analysts. Expectations of substantial gains from deals like the UK's COVID booster program and future post-pandemic market agreements have spurred investor confidence.
• Despite reduced forecasts for its RSV vaccine, the heightened revenue projections for Moderna's COVID-19 vaccines by analysts at the bank have likely instilled faith in the company's growth prospects among investors.
• The upbeat market reception to Moderna's potential expansion in global markets may have overshadowed the reservations raised by the 'Underperform' rating and $31 price target set by analysts. This hints at a disparity between analyst evaluations and market sentiments.

08.03.2026 - MRNA Stock was up 6.7%

• Moderna saw a significant rise in its stock price following an increase in price target to $35 from $30 by RBC Capital Markets, while maintaining a "Sector Perform" rating.
• This optimistic forecast signifies the market's confidence in Moderna's potential growth within the biotech sector.
• Analyst revisions, including the raised price target, indicate sustained interest and positivity towards Moderna's pipeline and future developments.
• The general positive sentiment towards Moderna may also be influenced by the broader optimistic outlook on biotech firms and healthcare technology progress, driving investor enthusiasm towards innovative solutions such as mRNA-based therapies.

24.03.2026 - MRNA Stock was down 5.6%

• Expectations for Moderna's (MRNA) Q1 2026 earnings are pessimistic, with analysts predicting a loss. Ongoing financial difficulties, negative margins, and insider selling are among the factors contributing to the downward movement.
• While potential positives like EU approval for mCOMBRIAX and a Phase 3 bird-flu vaccine trial could provide a boost, past funding reductions for its bird-flu program in the U.S. are seen as challenges affecting investor confidence.
• The market's general sentiment towards biotech companies may also be influencing the bearish trend. This is exemplified by the contrasting performance of Regeneron Pharmaceuticals, which received a positive rating reassessment amid the sector's fluctuations.

31.02.2026 - MRNA Stock was up 5.3%

• The positive investor sentiment towards the company's strategic shift towards oncology and next-generation therapies is likely the driving force behind the recent bullish movement of the company's stock.
• Favorable data on individualized neoantigen therapy for melanoma and the company's emphasis on cancer drug development are factors contributing to the market's positive response to the company's new direction.
• The selling of shares by an insider at a different company may have indirectly impacted the company's stock positively, potentially leading investors to view the company's strategic pivot more favorably.
• The company's proactive approach to diversifying its portfolio and focusing on innovative therapies appears to have resonated well with investors, leading to the upward movement in its stock price.

15.03.2026 - MRNA Stock was up 7.5%

• Moderna saw strong bullish movement today possibly due to the positive expectations surrounding its upcoming first-quarter 2026 financial results.
• The company's scheduled live conference call and webcast discussing financial results and future plans may have boosted investor confidence.
• Investor interest remains high in the biotech and healthcare sectors, exemplified by Moderna's positive market response in comparison to developments in other companies.
• Moderna's active engagement with investors and market optimism regarding its financial results likely contributed to the bullish movement in its stock price today.